Halozyme Therapeutics Inc (HALO)
38.46
-0.66
(-1.69%)
USD |
NASDAQ |
Apr 25, 16:00
38.46
0.00 (0.00%)
Pre-Market: 20:00
Halozyme Therapeutics Enterprise Value: 6.041B for April 25, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 25, 2024 | 6.041B |
| April 24, 2024 | 6.125B |
| April 23, 2024 | 6.106B |
| April 22, 2024 | 6.073B |
| April 19, 2024 | 6.064B |
| April 18, 2024 | 5.958B |
| April 17, 2024 | 5.985B |
| April 16, 2024 | 6.031B |
| April 15, 2024 | 6.074B |
| April 12, 2024 | 6.060B |
| April 11, 2024 | 6.150B |
| April 10, 2024 | 6.145B |
| April 09, 2024 | 6.253B |
| April 08, 2024 | 6.225B |
| April 05, 2024 | 6.372B |
| April 04, 2024 | 6.202B |
| April 03, 2024 | 6.265B |
| April 02, 2024 | 6.291B |
| April 01, 2024 | 6.404B |
| March 28, 2024 | 6.322B |
| March 27, 2024 | 6.329B |
| March 26, 2024 | 6.246B |
| March 25, 2024 | 6.290B |
| March 22, 2024 | 6.246B |
| March 21, 2024 | 6.264B |
| Date | Value |
|---|---|
| March 20, 2024 | 6.284B |
| March 19, 2024 | 6.339B |
| March 18, 2024 | 6.283B |
| March 15, 2024 | 6.345B |
| March 14, 2024 | 6.336B |
| March 13, 2024 | 6.407B |
| March 12, 2024 | 6.484B |
| March 11, 2024 | 6.388B |
| March 08, 2024 | 6.456B |
| March 07, 2024 | 6.453B |
| March 06, 2024 | 6.451B |
| March 05, 2024 | 6.415B |
| March 04, 2024 | 6.354B |
| March 01, 2024 | 6.377B |
| February 29, 2024 | 6.212B |
| February 28, 2024 | 6.197B |
| February 27, 2024 | 6.216B |
| February 26, 2024 | 6.194B |
| February 23, 2024 | 6.307B |
| February 22, 2024 | 6.201B |
| February 21, 2024 | 6.028B |
| February 20, 2024 | 5.729B |
| February 16, 2024 | 5.742B |
| February 15, 2024 | 5.718B |
| February 14, 2024 | 5.610B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
1.900B
Minimum
Mar 18 2020
9.276B
Maximum
Dec 02 2022
5.216B
Average
5.722B
Median
Jun 27 2023
Enterprise Value Benchmarks
| Johnson & Johnson | 360.21B |
| Globus Medical Inc | 6.718B |
| Denali Therapeutics Inc | 1.098B |
| AIM ImmunoTech Inc | 7.904M |
| Protalix BioTherapeutics Inc | 61.89M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 85.39M |
| Revenue (Quarterly) | 230.04M |
| Total Expenses (Quarterly) | 129.00M |
| EPS Diluted (Quarterly) | 0.65 |
| Gross Profit Margin (Quarterly) | 77.27% |
| Profit Margin (Quarterly) | 37.12% |
| Earnings Yield | 5.49% |
| Operating Earnings Yield | 6.54% |
| Normalized Earnings Yield | 5.025 |